National Cancer Institute; Notice of Closed Meetings, 6879 [2022-02476]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 25 / Monday, February 7, 2022 / Notices
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 827–4471, ramadanir@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: February 1, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–02469 Filed 2–4–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
jspears on DSK121TN23PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; A
Multilevel Approach to Connecting
Underrepresented Populations to Clinical
Trials (CUSP2CT).
Date: March 9, 2022.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W140, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: David G. Ransom, Ph.D.,
Chief, Scientific Review Officer, Special
VerDate Sep<11>2014
17:36 Feb 04, 2022
Jkt 256001
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W140,
Rockville, Maryland 20850, 240–276–6351,
david.ransom@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; The Role of
Epstein Barr Virus (EBV) Infection in NonHodgkin Lymphoma (NHL) and Hodgkin
Disease (HD) Development with or without
an Underlying HIV Infection (U01).
Date: March 24, 2022.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W104, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Robert F. Gahl, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9606 Medical
Center Drive, Room 7W104, Rockville,
Maryland 20850, 240–276–7869, robert.gahl@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; R13
Conference Grant Review.
Date: March 24, 2022.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W552, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Jeanette Irene Marketon,
Ph.D., Scientific Review Officer, Program
Coordination and Referral Branch, Division
of Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W552, Rockville, Maryland 20850,
240–276–6780, jeanette.marketon@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; TEP–11:
SBIR Contract Review Meeting.
Date: March 31, 2022.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W126, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Susan Lynn Spence, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W126, Rockville, Maryland
20850, 240–620–0819, susan.spence@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Cancer
Center Support Grant.
Date: May 12, 2022.
Time: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W612, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: CAPT Shari Williams
Campbell, DPM, MSHS, Scientific Review
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
6879
Officer, Resources and Training Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W612, Rockville,
Maryland 20850, 240–276–7381,
shari.campbell@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 2, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–02476 Filed 2–4–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Elizabeth Pitts, Ph.D., 240–669–5299;
elizabeth.pitts@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement may be required
to receive any unpublished information.
SUPPLEMENTARY INFORMATION:
Technology description follows:
SUMMARY:
Monoclonal Antibodies To Prevent or
Treat SARS–CoV–2 Infection
Description of Technology
The ongoing COVID–19 pandemic,
caused by severe respiratory syndrome
coronavirus 2 (SARS–CoV–2), has
E:\FR\FM\07FEN1.SGM
07FEN1
]]>Agencies
[Federal Register Volume 87, Number 25 (Monday, February 7, 2022)]
[Notices]
[Page 6879]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-02476]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; A Multilevel Approach to Connecting Underrepresented
Populations to Clinical Trials (CUSP2CT).
Date: March 9, 2022.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W140, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: David G. Ransom, Ph.D., Chief, Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W140, Rockville, Maryland 20850, 240-276-6351,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; The Role of Epstein Barr Virus (EBV) Infection in Non-Hodgkin
Lymphoma (NHL) and Hodgkin Disease (HD) Development with or without
an Underlying HIV Infection (U01).
Date: March 24, 2022.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W104, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: Robert F. Gahl, Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9606 Medical Center Drive, Room
7W104, Rockville, Maryland 20850, 240-276-7869, [email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; R13 Conference Grant Review.
Date: March 24, 2022.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W552, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: Jeanette Irene Marketon, Ph.D., Scientific
Review Officer, Program Coordination and Referral Branch, Division
of Extramural Activities, National Cancer Institute, NIH, 9609
Medical Center Drive, Room 7W552, Rockville, Maryland 20850, 240-
276-6780, [email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; TEP-11: SBIR Contract Review Meeting.
Date: March 31, 2022.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W126, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: Susan Lynn Spence, Ph.D., Scientific Review
Officer, Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W126, Rockville, Maryland 20850, 240-620-0819,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; Cancer Center Support Grant.
Date: May 12, 2022.
Time: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W612, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: CAPT Shari Williams Campbell, DPM, MSHS,
Scientific Review Officer, Resources and Training Review Branch,
Division of Extramural Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W612, Rockville, Maryland 20850,
240-276-7381, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: February 2, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-02476 Filed 2-4-22; 8:45 am]
BILLING CODE 4140-01-P
